サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566982

ウイルスベクターとプラスミドDNA製造市場：ベクタータイプ別、ワークフロー別、用途別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus , Lentivirus, Plasmids, Others), By Workflow By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ウイルスベクターとプラスミドDNA製造市場：ベクタータイプ別、ワークフロー別、用途別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ウイルスベクターとプラスミドDNA製造市場

ウイルスベクターとプラスミドDNA製造市場は、2023年に53億米ドルと評価され、2024～2033年にかけてCAGR 20.4%で成長し、2033年には340億米ドルに達すると予測されています。

ウイルスベクターとプラスミドDNAは遺伝子工学の重要なコンポーネントであり、遺伝子治療やワクチン生産など多様な目的に利用されています。ウイルスベクターは、遺伝子発現または細胞DNAへの遺伝物質の組み込みによって、遺伝情報を細胞に伝達するために使用される分子ビヒクルの一形態です。プラスミドDNAは、細菌に存在する染色体外環状DNAです。遺伝子クローニングや遺伝子治療のためのベクターとして機能します。ウイルスベクターやプラスミドDNAの製造は、細胞培養システム、精製プロセス、細菌発酵など様々な方法によって行われます。

遺伝性疾患の有病率の増加と技術の進歩が遺伝子治療の実施を容易にし、それによってウイルスベクターとプラスミドDNA製造市場の成長を促進しています。さらに、投資の急増による研究開発活動の増加や、政府と食品医薬品局などの規制機関からの支援が、ウイルスベクターとプラスミドDNAの製造需要を押し上げています。製造の拡大性を高めるために、AIやMLアルゴリズムを使用する動向が目立ってきています。アルゴリズムは、ベクターとプラスミドの生産を最大化するための正確な要件と理想的な条件を特定するのに役立ちます。

しかし、小さな異物が生産バッチ全体を台無しにする可能性があるため、製造中の汚染を防ぐことは難しい課題です。この課題は、ウイルスベクターとプラスミドDNA製造市場の成長を大幅に抑制します。加えて、製造に必要な機器の調達やメンテナンスは非常に高価であるため、小規模な企業や研究所の投資が制限され、市場成長の妨げとなっています。さらに、世界各国における規制プロセスの相違が、特定の地域におけるベクターやプラスミドの有用性を制限しています。例えば、欧州のガイドラインでは、製造の全段階において現行の適正製造基準への準拠が義務付けられています。これとは対照的に、米国食品医薬品局（FDA）では、製品開発の第1段階では、一部の材料や関連するすべての属性、あるいは許容基準が不明なままであることを容認しています。

セグメントレビュー

ウイルスベクターとプラスミドDNA製造市場は、ベクタータイプ、ワークフロー、アプリケーション、エンドユーザー、地域に区分されます。ベクタータイプ別では、アデノウイルス、レトロウイルス、アデノ随伴ウイルス（AAV）、レンチウイルス、プラスミド、その他に分けられます。ワークフローにより、上流製造と下流製造に二分されます。用途別では、アンチセンス＆RNAi療法、アンチセンス＆RNAi療法、細胞療法、ワクチン療法、研究用途に分類されます。エンドユーザー別では、製薬・バイオ医薬品企業と研究機関に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

主要調査結果

ベクタータイプ別では、アデノ随伴ウイルス（AAV）セグメントが2023年の市場を独占しました。

ワークフロー別では、下流製造セグメントが2023年に高い市場シェアを占めました。

用途別では、ワクチン接種セグメントが2023年に市場で高いシェアを獲得しました。

エンドユーザー別では、研究機関セグメントが2023年に高シェアを獲得しました。

地域別では、北米が2023年に最も高い収益を上げました。

本レポートのカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 ウイルスベクターとプラスミドDNA製造市場：ベクタータイプ別

  • 市場概要
  • アデノウイルス
  • レトロウイルス
  • アデノ関連ウイルス（AAV）
  • レンチウイルス
  • プラスミド
  • その他

第5章 ウイルスベクターとプラスミドDNA製造市場：ワークフロー別

  • 市場概要
  • 上流製造
  • 下流製造

第6章 ウイルスベクターとプラスミドDNA製造市場：用途別

  • 市場概要
  • アンチセンスRNAi療法
  • アンチセンスRNAi療法
  • 細胞療法
  • ワクチン療法
  • 研究用途

第7章 ウイルスベクターとプラスミドDNA製造市場：エンドユーザー別

  • 市場概要
  • 製薬バイオ医薬品企業
  • 研究機関

第8章 ウイルスベクターとプラスミドDNA製造市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のウイルスベクターとプラスミドDNA製造市場
    • カナダのウイルスベクターとプラスミドDNA製造市場
    • メキシコのウイルスベクターとプラスミドDNA製造市場
  • 欧州
    • 主要市場動向と機会
    • ドイツのウイルスベクターとプラスミドDNA製造市場
    • フランスのウイルスベクターとプラスミドDNA製造市場
    • 英国のウイルスベクターとプラスミドDNA製造市場
    • イタリアのウイルスベクターとプラスミドDNA製造市場
    • スペインのウイルスベクターとプラスミドDNA製造市場
    • その他の欧州のウイルスベクターとプラスミドDNA製造市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本のウイルスベクターとプラスミドDNA製造市場
    • 中国のウイルスベクターとプラスミドDNA製造市場
    • オーストラリアのウイルスベクターとプラスミドDNA製造市場
    • インドのウイルスベクターとプラスミドDNA製造市場
    • 韓国のウイルスベクターとプラスミドDNA製造市場
    • その他のアジア太平洋のウイルスベクターとプラスミドDNA製造市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのウイルスベクターとプラスミドDNA製造市場
    • サウジアラビアのウイルスベクターとプラスミドDNA製造市場
    • 南アフリカのウイルスベクターとプラスミドDNA製造市場
    • その他のラテンアメリカ・中東・アフリカのウイルスベクターとプラスミドDNA製造市場

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第10章 企業プロファイル

  • Merck KGaA
  • Lonza Group AG
  • FUJIFILM Corporation
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent Inc.
  • WuXi Biologics.
  • TakarBio Inc
  • Waisman Biomanufacturing, LLC
  • Genezen Laboratories
目次
Product Code: A324540

Viral Vectors and Plasmid DNA Manufacturing Market

The viral vectors and plasmid DNA manufacturing market was valued at $5.3 billion in 2023 and is projected to reach $34.0 billion by 2033, growing at a CAGR of 20.4% from 2024 to 2033.

Viral vector and plasmid DNA are the crucial components of genetic engineering, utilized for diverse purposes such as gene therapy and vaccine production. A viral vector is a form of molecular vehicle used to transfer genetic information to the cells either through gene expression or integration of genetic material into the cell's DNA. Plasmid DNA is an extrachromosomal circular piece of DNA present in bacteria. It serves as a vector for gene cloning, and gene therapy. The manufacturing of viral vectors and plasmid DNA is accomplished through various methods such as cell culture systems, purification processes, or bacterial fermentation.

Increase in the prevalence of genetic disorders and advancements in technology have facilitated the execution of gene therapies, thereby driving the growth of the viral vectors and plasmid DNA manufacturing market. In addition, rise in R&D activities due to surge in investments & support from government and regulatory agencies such as the Food and Drug administration is boosting the demand for the manufacturing for viral vectors and plasmid DNA. To enhance the scalability of production, the trend of using AI and ML algorithms is gaining prominence. The algorithm helps in identifying the precise requirements and ideal conditions to maximize the production of vectors and plasmid.

However, preventing contamination during manufacturing is challenging as a tiny foreign particle is capable of spoiling the entire production batch. This challenge significantly restrains the growth of the viral vectors and plasmid DNA manufacturing market. In addition, the procurement and maintenance of the equipment required for production is highly expensive, which limits several small-scale firms and laboratories from investing, hence hampering the market growth. Moreover, discrepancies in the regulatory process across the globe restrict the utility of the vectors and plasmid in certain regions. For instance, the European guidelines have mandated the compliance of products with the current good manufacturing practices standards at all stages of production. Contrarily, as per the U.S. Food and Drug Administration, it is acceptable that some materials and all relevant attributes or acceptance criteria remain unknown at stage 1 of product development.

Segment Review

The viral vectors and plasmid DNA manufacturing market is segmented into vector type, workflow, application, end user, and region. On the basis of vector type, the market is divided into adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Depending on workflow, it is bifurcated into upstream manufacturing and downstream manufacturing. As per application, it is classified into antisense & RNAi therapy, antisense & RNAi therapy, cell therapy, vaccinology, and research applications. According to end user, it is categorized into pharmaceutical & biopharmaceutical companies and research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of vector type, the adeno-associated virus (AAV) segment dominated the market in 2023.

Depending on workflow, the downstream manufacturing segment accounted for a high market share in 2023.

As per application, the vaccinology segment acquired a high stake in the market in 2023.

According to end user, the research institutes segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global viral vectors and plasmid DNA manufacturing market include Merck KGaA, Lonza Group AG, FUJIFILM Corporation, thermo fisher scientific, Cobra Biologics, Catalent Inc., WuXi Biologics., TakarBio Inc, Waisman Biomanufacturing, LLC, and Genezen laboratories. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

By Workflow

  • Upstream Manufacturing
  • Downstream Manufacturing

By Application

  • Antisense RNAi Therapy
  • Antisense RNAi Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

By End User

  • Pharmaceutical Biopharmaceutical Companies
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Merck KGaA
    • Lonza Group AG
    • FUJIFILM Corporation
    • Thermo Fisher Scientific Inc.
    • Cobra Biologics
    • Catalent Inc.
    • WuXi Biologics.
    • TakarBio Inc
    • Waisman Biomanufacturing, LLC
    • Genezen laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Vector Type
  • 4.2. Adenovirus
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Retrovirus
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Adeno-Associated Virus (AAV)
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Lentivirus
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Plasmids
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country
  • 4.7. Others
    • 4.7.1. Key Market Trends, Growth Factors and Opportunities
    • 4.7.2. Market Size and Forecast, By Region
    • 4.7.3. Market Share Analysis, By Country

CHAPTER 5: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Workflow
  • 5.2. Upstream Manufacturing
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Downstream Manufacturing
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Application
  • 6.2. Antisense RNAi Therapy
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Antisense RNAi Therapy
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Cell Therapy
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Vaccinology
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country
  • 6.6. Research Applications
    • 6.6.1. Key Market Trends, Growth Factors and Opportunities
    • 6.6.2. Market Size and Forecast, By Region
    • 6.6.3. Market Share Analysis, By Country

CHAPTER 7: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By End User
  • 7.2. Pharmaceutical Biopharmaceutical Companies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Research Institutes
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country

CHAPTER 8: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Vector Type
    • 8.2.3. Market Size and Forecast, By Workflow
    • 8.2.4. Market Size and Forecast, By Application
    • 8.2.5. Market Size and Forecast, By End User
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.7.1. Market Size and Forecast, By Vector Type
      • 8.2.7.2. Market Size and Forecast, By Workflow
      • 8.2.7.3. Market Size and Forecast, By Application
      • 8.2.7.4. Market Size and Forecast, By End User
    • 8.2.8. Canada Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.8.1. Market Size and Forecast, By Vector Type
      • 8.2.8.2. Market Size and Forecast, By Workflow
      • 8.2.8.3. Market Size and Forecast, By Application
      • 8.2.8.4. Market Size and Forecast, By End User
    • 8.2.9. Mexico Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.9.1. Market Size and Forecast, By Vector Type
      • 8.2.9.2. Market Size and Forecast, By Workflow
      • 8.2.9.3. Market Size and Forecast, By Application
      • 8.2.9.4. Market Size and Forecast, By End User
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Vector Type
    • 8.3.3. Market Size and Forecast, By Workflow
    • 8.3.4. Market Size and Forecast, By Application
    • 8.3.5. Market Size and Forecast, By End User
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.7.1. Market Size and Forecast, By Vector Type
      • 8.3.7.2. Market Size and Forecast, By Workflow
      • 8.3.7.3. Market Size and Forecast, By Application
      • 8.3.7.4. Market Size and Forecast, By End User
    • 8.3.8. France Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.8.1. Market Size and Forecast, By Vector Type
      • 8.3.8.2. Market Size and Forecast, By Workflow
      • 8.3.8.3. Market Size and Forecast, By Application
      • 8.3.8.4. Market Size and Forecast, By End User
    • 8.3.9. UK Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.9.1. Market Size and Forecast, By Vector Type
      • 8.3.9.2. Market Size and Forecast, By Workflow
      • 8.3.9.3. Market Size and Forecast, By Application
      • 8.3.9.4. Market Size and Forecast, By End User
    • 8.3.10. Italy Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.10.1. Market Size and Forecast, By Vector Type
      • 8.3.10.2. Market Size and Forecast, By Workflow
      • 8.3.10.3. Market Size and Forecast, By Application
      • 8.3.10.4. Market Size and Forecast, By End User
    • 8.3.11. Spain Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.11.1. Market Size and Forecast, By Vector Type
      • 8.3.11.2. Market Size and Forecast, By Workflow
      • 8.3.11.3. Market Size and Forecast, By Application
      • 8.3.11.4. Market Size and Forecast, By End User
    • 8.3.12. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.12.1. Market Size and Forecast, By Vector Type
      • 8.3.12.2. Market Size and Forecast, By Workflow
      • 8.3.12.3. Market Size and Forecast, By Application
      • 8.3.12.4. Market Size and Forecast, By End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Vector Type
    • 8.4.3. Market Size and Forecast, By Workflow
    • 8.4.4. Market Size and Forecast, By Application
    • 8.4.5. Market Size and Forecast, By End User
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.7.1. Market Size and Forecast, By Vector Type
      • 8.4.7.2. Market Size and Forecast, By Workflow
      • 8.4.7.3. Market Size and Forecast, By Application
      • 8.4.7.4. Market Size and Forecast, By End User
    • 8.4.8. China Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.8.1. Market Size and Forecast, By Vector Type
      • 8.4.8.2. Market Size and Forecast, By Workflow
      • 8.4.8.3. Market Size and Forecast, By Application
      • 8.4.8.4. Market Size and Forecast, By End User
    • 8.4.9. Australia Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.9.1. Market Size and Forecast, By Vector Type
      • 8.4.9.2. Market Size and Forecast, By Workflow
      • 8.4.9.3. Market Size and Forecast, By Application
      • 8.4.9.4. Market Size and Forecast, By End User
    • 8.4.10. India Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.10.1. Market Size and Forecast, By Vector Type
      • 8.4.10.2. Market Size and Forecast, By Workflow
      • 8.4.10.3. Market Size and Forecast, By Application
      • 8.4.10.4. Market Size and Forecast, By End User
    • 8.4.11. South Korea Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.11.1. Market Size and Forecast, By Vector Type
      • 8.4.11.2. Market Size and Forecast, By Workflow
      • 8.4.11.3. Market Size and Forecast, By Application
      • 8.4.11.4. Market Size and Forecast, By End User
    • 8.4.12. Rest of Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.12.1. Market Size and Forecast, By Vector Type
      • 8.4.12.2. Market Size and Forecast, By Workflow
      • 8.4.12.3. Market Size and Forecast, By Application
      • 8.4.12.4. Market Size and Forecast, By End User
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Vector Type
    • 8.5.3. Market Size and Forecast, By Workflow
    • 8.5.4. Market Size and Forecast, By Application
    • 8.5.5. Market Size and Forecast, By End User
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.7.1. Market Size and Forecast, By Vector Type
      • 8.5.7.2. Market Size and Forecast, By Workflow
      • 8.5.7.3. Market Size and Forecast, By Application
      • 8.5.7.4. Market Size and Forecast, By End User
    • 8.5.8. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.8.1. Market Size and Forecast, By Vector Type
      • 8.5.8.2. Market Size and Forecast, By Workflow
      • 8.5.8.3. Market Size and Forecast, By Application
      • 8.5.8.4. Market Size and Forecast, By End User
    • 8.5.9. South Africa Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.9.1. Market Size and Forecast, By Vector Type
      • 8.5.9.2. Market Size and Forecast, By Workflow
      • 8.5.9.3. Market Size and Forecast, By Application
      • 8.5.9.4. Market Size and Forecast, By End User
    • 8.5.10. Rest of LAMEA Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.10.1. Market Size and Forecast, By Vector Type
      • 8.5.10.2. Market Size and Forecast, By Workflow
      • 8.5.10.3. Market Size and Forecast, By Application
      • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Merck KGaA
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Lonza Group AG
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. FUJIFILM Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Thermo Fisher Scientific
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Cobra Biologics
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Catalent Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. WuXi Biologics.
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. TakarBio Inc
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Waisman Biomanufacturing, LLC
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Genezen Laboratories
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments